REGEN-αGEEK

REGEN-αGEEK is a clinical-stage biotechnology company based in Kyoto, Japan, dedicated to developing treatments for rare and intractable diseases using iPS cell technology. Spun out of Kyoto University's Center for iPS Cell Research and Application (CiRA), the company utilizes a proprietary phenotypic screening platform to identify drug candidates by modeling human diseases in vitro. Their most prominent achievement is the repositioning of sirolimus for the treatment of Fibrodysplasia Ossificans Progressiva (FOP), which has progressed into clinical trials. The company's approach focuses on bridging the gap between basic stem cell research and clinical application to address high unmet medical needs. REGEN-αGEEK continues to leverage its platform to expand its pipeline into other musculoskeletal and rare genetic disorders.